Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2006 Mar 27;94(6):798-805.
doi: 10.1038/sj.bjc.6603011.

FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG)

J Souglakos  1 , N Androulakis, K Syrigos, A Polyzos, N Ziras, A Athanasiadis, S Kakolyris, S Tsousis, Ch Kouroussis, L Vamvakas, A Kalykaki, G Samonis, D Mavroudis, V Georgoulias
Affiliations
Clinical Trial

FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG)

J Souglakos et al. Br J Cancer. .

Abstract

To compare the efficacy and toxicity of oxaliplatin (L-OHP) in combination with irinotecan (CPT-11), 5-fluorouracil (5-FU) and leucovorin (LV) (FOLFOXIRI) vs irinotecan and 5-FU/LV (FOLFIRI) as first-line treatment of patients with metastatic colorectal cancer (MCC). A total of 283 chemotherapy-naïve patients with MCC were enrolled (FOLFIRI arm: n=146; FOLFOXIRI arm: n=137). In the FOLFOXIRI arm, CPT-11 (150 mg m(-2)) was given on d1, L-OHP (65 mg m(-2)) on d2, LV (200 mg m(-2)) on days 2 and 3 and 5-FU (400 mg m(-2) as i.v. bolus and 600 mg m(-2) as 22 h i.v. continuous infusion) on days 2 and 3. In the FOLFIRI arm, CPT-11 (180 mg m(-2)) was given on d1 whereas LV and 5-FU were administered in the same way as in the FOLFOXIRI regimen. Both regimens were administered every 2 weeks. There was no difference in terms of overall survival (median OS: 19.5 and 21.5 months, for FOLFIRI and FOLFOXIRI, respectively; P=0.337), median time to disease progression (FOLFIRI: 6.9 and FOLFOXIRI: 8.4 months; P=0.17), response rates (33.6 and 43% for FOLFIRI and FOLFOXIRI, respectively; P=0.168). Patients treated with FOLFOXIRI had a significantly higher incidence of alopecia (P=0.0001), diarrhoea (P=0.0001) and neurosensory toxicity (P=0.001) compared with patients treated with FOLFIRI. The present study failed to demonstrate any superiority of the FOLFOXIRI combination compared with the FOLFIRI regimen, although the observed median OS is one of the best ever reported in the literature.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Chemotherapy regimens (A) FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) and (B) FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan).
Figure 2
Figure 2
Trial profile.
Figure 3
Figure 3
Kaplan–Meier overall survival of patients treated with FOLFIRI and FOLFOXIRI.
Figure 4
Figure 4
Kaplan–Meier time to tumour progression (TTP) of patients treated with FOLFIRI and FOLFOXIRI.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. American Cancer Society. Cancer Facts and Figures. Atlanta, GA: American Cancer Society, 2005. http://www.cancer.org/downloads/STT/CAFF2005f4PWsecured.pdf. Assessed March 8, 2005
    1. Bleiberg H (1998) Oxaliplatin (L-OHP): a new reality in colorectal cancer. Br J Cancer 77(Suppl 4): 1–3 - PMC - PubMed
    1. Caussanel JP, Lévi F, Brienza S, Misset JL, Itzhaki M, Adam R, Milano G, Hecquet B, Mathe G (1990) Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm modulated rate compared with constant rate. J Natl Cancer Inst 82: 1046–1050 - PubMed
    1. Cox DR (1972) Regression models and life-tables. J R Stat Soc 34B: 187–220
    1. de Gramont A, Bosset JF, Milan C, Rougier P, Bouche O, Etienne PL, Morvan F, Louvet C, Guillot T, Francois E, Bedenne L (1997) Randomized trial comparing monthly low-dose leukovorin and fluorouracil bolus with bimonthly high dose leukovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 14: 808–815 - PubMed

Publication types

MeSH terms

Supplementary concepts